Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.
Type:
Grant
Filed:
January 31, 2017
Date of Patent:
January 1, 2019
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE LORRAINE, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU), UNIVERSITE PARIS DIDEROT-PARIS 7, UNIVERSITE PARIS DESCARTES
Inventors:
Frederic Jaisser, Nicolette Farman, Antoine Tarjus, Patrick Rossignol, Faiez Zannad
Abstract: A method for collecting and a device for sensing at least one electrophysiological signal, as well as to a system including at least one such device. The device for sensing at least one electrophysiological signal from a living subject subjected to at least one electromagnetic field, includes elements, such as electrodes, which are placed on the subject for the physical acquisition of at least one electrophysiological signal and at least elements for the pre-processing of the at least one sampled electrophysiological signal. The sensor device (1) is characterised in that it also includes additional elements (7, 8) for measuring or determining at least one characteristic of the electromagnetic environment at or close to the electrophysiological signal acquisition point(s) or zone(s) on the subject.
Type:
Application
Filed:
April 25, 2008
Publication date:
July 29, 2010
Applicants:
SCHILLER MEDICAL, UNIVERSITE HENRI POINCARE-NANCY I, UNIVERSITE DE STRASBOURG, CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY
Inventors:
Jacques Felblinger, Michel Kraemer, Jean-Philippe Blonde, Roger Abacherli, Vincent Frick, Johann-Jakob Schmid